Compare Bristol-Myers Squibb Co (BMY) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs PayPal Holdings, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.81 (market cap $132.45B), while PayPal Holdings, Inc. trades at $58.87 (market cap $50.53B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.6× PayPal Holdings, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.89%). Which is the better fit depends on your goals.
| BMY | PYPL | |
|---|---|---|
Market Cap | $132.45B | $50.53B |
Sector | Health | Financials |
52-Week High | $65.89 | $76.13 |
52-Week Low | $42.60 | $39.08 |
Enterprise Value | $166.44B | $52.68B |
Dividend Yield | 3.89% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.
BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.
PayPal (PYPL) trades at $59.07, down 1.19% on the day, with a bullish technical outlook supported by moving averages and strong cash flow. Recent earnings beat expectations, with Q2 2026 EPS of $1.38 exceeding the $1.28 consensus, while revenue grew 4.8% year-over-year. The company raised full-year 2026 guidance, signaling confidence in its turnaround under new leadership, amid acquisition interest from Stripe and Advent International at a $53 billion valuation rejected by the board.
PYPL presents a value opportunity with a low P/E of 11.17 and robust free cash flow, but faces risks from competitive pressures and economic sensitivity. Analyst consensus is mixed with 35.7% buy ratings, though institutional buying and undervaluation narratives support upside potential if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
